Montelukast as a Controller of Atopic Syndrome

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2007

Study Completion Date

July 31, 2007

Conditions

Seasonal Allergic RhinitisAllergic ConjunctivitisAtopic EczemaAsthma

Interventions

DRUG

montelukast

10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner

Trial Locations (1)

Skin and Allergy Hospital, Helsinki University Hospital, Helsinki

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Helsinki

OTHER

NCT00559546 - Montelukast as a Controller of Atopic Syndrome | Biotech Hunter | Biotech Hunter